Senses Disorder TRIZ Cases

Proteas inhibitors in placental tissue preparations increase protein concentrations and stability, resolving manufacturing complexity trade-offs.

Anti-sortilin antibodies inhibit sortilin-mediated apoptosis to prevent diabetic retinopathy progression.

Biodegradable formulations maintain therapeutic drug levels over extended periods while eliminating toxic side effects from high initial doses.

Segmented USH2A minigenes fit within AAV packaging limits, restoring protein function while bypassing size constraints.

Topical microplasmin degrades fibrin clots to prevent scar tissue closure of the drainage channel, sustaining intraocular pressure reduction.

Glucagon receptor antagonist compounds inhibit hepatic glucose production to lower plasma glucose levels in type 2 diabetes treatment.

Oat extract avenanthramide reduces reactive oxygen species by 20 percent to prevent noise-induced hearing loss and ototoxicity.

Feeder-free culture systems with TGFβ superfamily members increase RPE cell yield, reducing labor intensity for clinical applications.

CFTR-activating compounds enhance tear secretion and intestinal fluid motility.

Amantadine nitrate compounds integrate NMDA receptor inhibition with nitric oxide release to block neurodegenerative processes in Alzheimer's disease.

Aqueous (-) erythro α-methyl epinephrine increases cerebral blood flow via alpha-adrenergic receptor activation.

SLIM riboswitches enable precise retinal gene control via dual silencing mechanisms, reducing treatment frequency and toxicity for AMD and glaucoma.

Screening methods identify candidate therapeutics by culturing intraocular microbiota to inhibit pathogenic microorganism growth.

Intermittent dosing reduces systemic immunosuppression, restoring immune responsiveness while controlling neuroinflammation in the CNS.

Nitazoxanide treats cholestatic diseases by reducing bile acid levels and alpha-SMA expression across multiple organs.

Sustained release HB-EGF formulations close chronic tympanic membrane perforations, reducing invasive surgical complexity.

Non-ionic detergents in the homogenization buffer prevent endotoxin binding to Annexin A5, eliminating centrifugation steps and boosting yield.

Tetrahydropyrido[4,3-d]pyrimidine compounds improve potency and selectivity for treating neurological and inflammatory disorders.

Selective MGL inhibition elevates 2-AG in targeted brain areas, reducing pain and psychiatric disorders without broad cannabinoid side effects.

A nutraceutical composition combining cyanidin-3-O-glucoside and verbascoside to enhance retinal cell viability.

A refillable reservoir uses a sintered porous structure to control therapeutic agent diffusion rates for extended release.

Modifying molecular parameters of (R)-2-methyl-piperazine derivatives reduces QT prolongation risk while maintaining therapeutic efficacy.

A polymeric delivery system solubilizes prostaglandins for stable ophthalmic use.

LNA-modified antisense oligonucleotides target TGF-beta2 mRNA sequences to suppress protein expression while minimizing off-target effects.

S1P5 receptor modulators shift ceramide balance to enhance oligodendrocyte survival, treating demyelination disorders beyond immunoregulation.

Phenylacetic acid derivatives selectively inhibit cyclooxygenase-2 to relieve inflammation without causing gastrointestinal ulceration.

Glucagon receptor antagonists block hepatic glucose output, reducing insulin dosage and preventing hypoglycemia in type 1 diabetes.

Combines an SGLT2 inhibitor with an insulin secretagogue to lower blood glucose levels.

Applying surface antigen markers to extract specific cell subsets, resolving the contradiction between therapeutic efficacy and ectopic tissue formation risks.

SR-BI SNP screening predicts low progesterone levels and poor fetal viability, enabling early intervention strategies.

Humanized anti-CD19 antibodies target and deplete B cells through complement-dependent cytotoxicity.

Segmented nucleic acid aptamers target C5 to reduce toxicity while preventing neovascularization in non-exudative AMD.

Antibodies bind misfolded transthyretin to inhibit aggregation, addressing tissue damage from amyloid fibril formation.

Thermoreversible BDNF gel eliminates frequent injections and osmotic damage.

Amide substituted indazoles enhance PARP inhibition potency while reducing off-target effects and chemotherapy toxicity.

Lutein ophthalmic composition uses polyvinyl alcohol to increase viscosity and extend retention time on the ocular surface.

Sodium acetate buffering and non-ionic sugar tonicity prevent dimeric impurity formation in stressed aflibercept ophthalmic compositions.

A chimeric mRNA 3' end merges a histone stem-loop with a polyadenylation signal to boost translational efficiency.

Pyridinone and pyridazinone derivatives inhibit poly(ADP-ribose)polymerase enzymes to address weak activity and off-target effects of current PARP inhibitors.

Formula I and Ia compounds inhibit diacylglycerol acyltransferase 2 to lower liver fat, improving insulin sensitivity in type 2 diabetes treatment.

Botulinum toxin penetrates the eye through axoplasmic transport to reach intra-ocular tissues without causing neuromuscular effects.

Intraocular fibromodulin composition reduces corneal haze and improves visual acuity by modulating collagen deposition during wound healing.

Specific structural modifications reduce birefringence to improve suitability for reflective displays.

Direct TMEM16A modulation by benzimidazules sustains anion secretion, resolving transient effects and receptor desensitization from indirect calcium pathways.